DanaherDHR
DHR
About: In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Employees: 63,000
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
120% more call options, than puts
Call options by funds: $1.53B | Put options by funds: $697M
4% more funds holding in top 10
Funds holding in top 10: 57 [Q4 2024] → 59 (+2) [Q1 2025]
0.52% less ownership
Funds ownership: 79.06% [Q4 2024] → 78.54% (-0.52%) [Q1 2025]
5% less funds holding
Funds holding: 2,277 [Q4 2024] → 2,168 (-109) [Q1 2025]
12% less capital invested
Capital invested by funds: $131B [Q4 2024] → $115B (-$16.3B) [Q1 2025]
17% less repeat investments, than reductions
Existing positions increased: 784 | Existing positions reduced: 950
28% less first-time investments, than exits
New positions opened: 151 | Existing positions closed: 209
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$215
7%
upside
Avg. target
$239
19%
upside
High target
$260
30%
upside
8 analyst ratings
8 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Conor McNamara | 25%upside $250 | Outperform Reiterated | 23 Apr 2025 |
Goldman Sachs Matthew Sykes | 20%upside $240 | Buy Maintained | 23 Apr 2025 |
Guggenheim Subbu Nambi | 25%upside $250 | Buy Reiterated | 23 Apr 2025 |
UBS Dan Leonard | 20%upside $240 | Buy Maintained | 23 Apr 2025 |
Baird Catherine Schulte | 12%upside $225 | Outperform Maintained | 23 Apr 2025 |
Financial journalist opinion
Based on 11 articles about DHR published over the past 30 days
Positive
Zacks Investment Research
3 days ago
CVS vs. DHR: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical Services stocks have likely encountered both CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Neutral
Business Wire
1 week ago
Prosperity Partners Completes Acquisition of Danaher Attig & Plante
CHICAGO--(BUSINESS WIRE)--Prosperity Partners (“Prosperity”), a Chicago-headquartered tax and accounting business backed by Unity Partners LP (“Unity Partners”), today announced that it has completed the acquisition of South Burlington, Vermont-based tax and accounting firm Danaher Attig & Plante (“DAP”). Terms of the private transaction were not disclosed. Founded in 2005 and led by Cathy Attig and Matt Johnson, DAP provides sophisticated tax advisory and compliance services to individuals.
Neutral
Business Wire
1 week ago
SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #Evocep--SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement.
Neutral
Business Wire
1 week ago
Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #AI--SCIEX announces three software ecosystem enhancements at ASMS, supporting the theme that “all science is data science now.”.
Neutral
Business Wire
1 week ago
SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #ZenoTOF--At ASMS 2025, SCIEX launches the ZenoTOF 8600 system, setting a new standard in accurate mass quantitation.
Positive
Zacks Investment Research
2 weeks ago
Danaher Partners With AstraZeneca to Support Precision Medicine
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
Neutral
PRNewsWire
2 weeks ago
Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics This partnership aims to create a framework for rapid diagnostics research, development and commercialization Danaher, through its Centers for Enabling Precision Medicine, will provide support in all aspects of the development cycle across diagnostic modalities WASHINGTON , May 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and technology innovator, announced today the launch of a partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize novel diagnostic tools and tests intended to help clinicians better determine which patients would most benefit from precision medicine treatments. "Precision medicines are more targeted than standard therapies and thus require precision diagnostics to determine which patients are most likely to benefit," said Julie Sawyer Montgomery, Danaher Executive Vice President.
Positive
CNBC Television
2 weeks ago
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see benefits from AI, and more.
Positive
Zacks Investment Research
2 weeks ago
CVS or DHR: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Negative
Zacks Investment Research
3 weeks ago
Why Is Danaher (DHR) Down 4.8% Since Last Earnings Report?
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
Charts implemented using Lightweight Charts™